## Agenda Item

### Wednesday, February 21

<table>
<thead>
<tr>
<th>Time</th>
<th>Purpose</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Welcome &amp; Introductions</td>
<td>Dr. Nancy Bennett (ACIP Chair), Dr. Amanda Cohn (ACIP Executive Secretary; CDC)</td>
</tr>
<tr>
<td>8:30</td>
<td>Hepatitis Vaccines</td>
<td>Dr. Jose Romero (ACIP, WG Chair), Dr. Aaron Harris (CDC/NCHHSTP), Dr. Sarah Schillie (CDC/NCHHSTP)</td>
</tr>
<tr>
<td>10:15</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Influenza Vaccines</td>
<td>Dr. Chip Walter (ACIP, WG Chair), Dr. Leonard Friedland (GSK), Ms. Lynnette Brammer (CDC/NCIRD), Dr. Brendan Flannery (CDC/NCIRD)</td>
</tr>
<tr>
<td>12:45</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:45</td>
<td>Evidence Based Recommendations</td>
<td>Dr. Grace Lee (ACIP, WG Chair), Dr. Wendy Carr (CDC/NCIRD)</td>
</tr>
<tr>
<td>2:30</td>
<td>Anthrax</td>
<td>Dr. David Stephens (ACIP, WG Chair), Dr. William Bower (CDC/NCEZID)</td>
</tr>
<tr>
<td>3:45</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>4:00</td>
<td>Human Papillomavirus (HPV) Vaccines</td>
<td>Dr. Peter Szilagyi (ACIP, WG Chair), Dr. Jorge Arana (CDC/NCEZID), Dr. Jim Donahue (Marshfield Clinic), Dr. Lauri Markowitz (CDC/NCIRD)</td>
</tr>
<tr>
<td>5:30</td>
<td>Public Comment</td>
<td></td>
</tr>
<tr>
<td>5:45</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>
Thursday, February 22

8:00  Agency Updates & Unfinished Business  
CDC, CMS, DoD, DVA, FDA, HRSA, IHS, NIH, NVPO

9:00  Pneumococcal
Introduction
PCV13 Effectiveness: Case Control Study
PCV13 Direct and Indirect Effects among Adults ≥65 Year Old
PCV13 effectiveness against pneumococcal pneumonia among U.S. Adults
Estimating Burden of Pneumococcal Pneumonia among Adults in the U.S. Progress of the research agenda to inform potential policy change

10:30  Vaccines and other biologics for prevention and treatment of healthcare-associated infections
Update

11:00  Break

11:30  Meningococcal Disease
Introduction
Epidemiology of meningococcal disease among college students – United States, 2014-2016

12:00  Japanese Encephalitis (JE) Vaccine
Introduction
Review of JE and work group plans

12:15  Vaccine Supply

12:20  Public Comment

12:30  Adjourn

**Acronyms**

- CDC: Centers for Disease Control & Prevention
- CMS: Centers for Medicare and Medicaid Services
- DoD: Department of Defense
- DVA: Department of Veterans Affairs
- FDA: Food and Drug Administration
- GRADE: Grading of Recommendations Assessment, Development and Evaluation
- HRSA: Health Resources and Services Administration
- IHS: Indian Health Service
- JE-VC: Vero cell culture-derived Japanese encephalitis
- NCHHSTP: National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
- NCIRD: National Center for Immunization & Respiratory Diseases [of CDC/OID]
- NCEZID: National Center for Emerging and Zoonotic Diseases [of CDC/OID]
- NCI: National Cancer Institute
- NIH: National Institutes of Health
- NVPO: National Vaccine Program Office
- PCV13: 13-valent pneumococcal conjugate vaccine
- VFC: Vaccines for Children
- WG: Work Group